ArticleLasers in medical science2025
Protocol for a randomized clinical trial on the efficacy of blue light emitting diode in the treatment of recurrent vulvovaginal candidiasis.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBlue light (BL) induces reactive oxygen species (ROS), exerting an antimicrobial effect. This study will assess its effectiveness in women with recurrent vulvovaginal candidiasis (RVVC).
methodsThis study was designed as a controlled, randomized, double-blind clinical trial. The intervention consists of applying a BL device with a wavelength of 401 ± 5 nm to the vulvovaginal region for 21 days, with two weekly sessions of 30 minutes each. The sample will consist of 51 women aged between 18 and 40 years, diagnosed with recurrent vaginal candidiasis and in a stable relationship. Participants will be randomly allocated to one of three groups: Group II: luconazole 200 mg; Group II: inactive BL in combination with luconazole 200 mg; Group III: active BL and luconazole 200 mg. The medication will be prescribed by a physician.
resultsParticipants will undergo assessments at baseline, after the first treatment, and on days 7, 14, 21, and the third day after the inal application to monitor outcomes. The primary outcome will be the absence of Candida Albicans (CA), while secondary outcomes include improvements in quality of life, sleep quality and reduction in levels of stress, anxiety and depression after treatment. Descriptive statistics and generalized models with Bonferroni post-tests will be used for intergroup comparisons, adopting p < 0.05.
conclusionBL is expected to emerge as a potential non-pharmacological alternative for reducing Candida Albicans fungal load, improving clinical symptoms, and enhancing the quality of life of women with RVVC.
Indexed as
Identifiers
40471351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.